Ted C Nark insider trades: Amneal Pharmaceuticals (AMRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ted reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | AMRX | ↓ Sell | 50,000 | $11.72 | $586K | Direct | Nov 19, 2025 (2d) |
| Aug 28, 2019 | AMRX | ↑ Buy | 50,000 | $2.39 | $120K | Direct | Aug 28, 2019 (0d) |
| Mar 12, 2007 | FTD | ↓ Sell | 63,190 | $17.50 | $1.1M | By FTD Co-Investment LLC | Mar 13, 2007 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AMRX insiders
Open-market trades in the last 12 months
About Ted C Nark's insider trades
Ted C Nark is a director at Amneal Pharmaceuticals (AMRX). Since Mar 12, 2007, Ted has reported 1 open-market purchase worth $120K and 2 sales worth $1.7M on SEC Form 4. In the last 12 months: 1 sale ($586K).
Their filings also include grants and awards (24 filings), option exercises (8 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.